NCT01934101终止1 期
A Phase 1 Double-blind, Randomised, Placebo-controlled, Dose Escalating Study to Assess the Safety and Tolerability of Single and Multiple Oral Doses of CHR-5154 and the Effect of the Fasted and Fed State on Pharmacokinetics of CHR-5154 and CHR-5426 in Healthy Male Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 64
- 试验地点
- 1
- 主要终点
- Number of volunteers with adverse events
研究概览
简要总结
Primary Objective:
• To determine the safety and tolerability of single and multiple ascending oral doses of CHR-5154 in healthy volunteers.
Secondary Objectives:
- To determine the pharmacokinetic profile of CHR-5154 and its metabolite CHR-5426.
- To compare the pharmacokinetic profile of CHR-5154 and CHR-5426 after a single dose of CHR-5154 in the fed and fasted state.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male volunteers aged 18-
- •Non-smokers from at least three months before receiving the first dose of study drug and for the duration of the study.
- •Body mass index (BMI) ≥ 18 and ≤ 32 kg/m
- •Body weight ≥ 50 kg and ≤ 120 kg at screening.
- •Able to voluntarily provide written informed consent to participate in the study.
- •Must understand the purposes and risks of the study and agree to follow the restrictions and schedule of procedures as defined in the protocol, as confirmed during the informed consent process.
- •Sexually active male volunteers must use two highly effective methods of contraception with their partners throughout the study and for 90 days after completion of the study.
- •Male volunteers must not donate sperm during the study and for 90 days after completion of the study.
- •Must be willing to consent to have data entered into The Over Volunteering Prevention System (TOPS).
- •The volunteer's primary care physician must confirm that there is nothing in their medical history that would preclude their enrolment into this clinical study
排除标准
- •Volunteers with history or presence of significant cardiovascular disease, pulmonary, hepatic, gallbladder or biliary tract, renal, haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychiatric disease or current infection.
- •Laboratory values at screening or baseline which are deemed to be clinically significant.
- •QTcF greater than 450 msec at screening.
- •Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
- •Current or history of drug or alcohol abuse or a positive drugs of abuse or alcohol test at screening or check-in.
- •Participation in a clinical drug study during the 90 days preceding the initial dose in this study.
- •Any clinically significant illness within 30 days prior to study drug administration.
- •Donation of blood or blood products within 90 days prior to study drug administration, or at any time during the study, except as required by this protocol.
- •Volunteers who have a history or presence of any significant drug allergy.
- •Use of any prescription or over-the-counter medication (including vitamins, herbal and mineral supplements) within 30 days prior to study drug administration until the end of the study, with the exception of occasional paracetamol approved by the Investigator.
- •Strenuous exercise, as judged by the Investigator, within 72 hours prior to screening, within 72 hours prior to study drug administration and for the duration of the study until after the post-study medical.
- •Weekly alcohol intake exceeding the equivalent of 21 units per week.
- •Consumption of alcoholic beverages within 24 hours prior to study drug administration and during study confinement.
- •Consumption of caffeine or xanthine-containing products within 24 hours prior to confinement and during study confinement.
- •Consumption of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade or other products containing grapefruit or Seville oranges within 7 days prior to confinement and during study confinement.
- •Volunteers who, in the opinion of the Investigator, are unsuitable for participation in the study.
研究组 & 干预措施
CHR-5154
Experimental
CHR-5154
干预措施: CHR-5154 (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Number of volunteers with adverse events
时间窗: upto 10 days in Single ascending dose phase and 16 days in the Multiple ascending dose phase
次要结局
- To compare the pharmacokinetic profile of CHR-5154 and CHR-5426 after a single dose of CHR-5154 in the fed and fasted state.(Upto 48 hours)
- To determine the pharmacokinetic profile of CHR-5154 and its metabolite CHR-5426.(upto 48 hrs post dose)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study to Assess the Safety of MEB-1170 in Healthy SubjectsPainNCT05748119Mebias Discovery, Inc72
已完成
1 期
Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy VolunteersMajor Depressive DisorderNCT02366364Naurex, Inc, an affiliate of Allergan plc15
终止
1 期
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With PsoriasisPsoriasisNCT03145948AbbVie12
已完成
1 期
Multiple Ascending Dose Study of GLPG0974 in Healthy SubjectsHealthyNCT01721980Galapagos NV32
终止
1 期
A Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female SubjectsPharmacokinetics of ASP7657Pharmacodynamics of ASP7657Healthy SubjectsNCT02108548Astellas Pharma Europe B.V.89